NEW YORK, April 25, 2019 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5771121/?utm_source=PRN
Idiopathic pulmonary fibrosis (IPF) is a progressive disease that results in the scarring of lung tissue and changes the lung's ability to function normally.The most common signs and symptoms of idiopathic pulmonary fibrosis are dyspnea and a persistent nonproductive cough.
Many affected individuals also experience a loss of appetite and gradual weight loss.IPF primarily occurs in older adults.
However, the causes are unknown.
The report "Idiopathic Pulmonary Fibrosis: Competitive Landscape to 2026", uses in-house analyst expertise to provide a competitive assessment of the disease marketplace.
This report provides -- The IPF pipeline consists of 132 drugs spanning all stages of development with approximately two-third of the drugs in the preclinical stage. The strength of the IPF pipeline is strong with 14 drugs, all with novel MOAs, in late-stage clinical development- Close to 43% of IPF clinical trials have been conducted in North America between 2010-2017. 66 clinical trials were recorded in North America between 2010-2017Overall, IPF clinical trials have had relatively high enrollment efficiencies in all phases except for Phase III, which had close to 84% efficiency- Phase II clinical trials had the highest enrollment efficiency (105%), which could be due to patients being more willing to participate due to increased confidence in the safety and efficacy of a late-stage drug
Companies mentioned: Roche, Boehringer Ingelheim, Zambon, Galapagos NV, Prometic Life Sciences Inc, Novartis, Biogen, Promedior, FibroGen
Scope- Pipeline Assessment-regional breakdown, promising late-stage products, early-stage pipeline by molecule type- Clinical Trials Assessment-trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics- Commercial Assessment-leading marketed products, current and future players- Competitive Landscape Analysis-key market events (2016-2026).
Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global IPF market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Download the full report: https://www.reportbuyer.com/product/5771121/?utm_source=PRN
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +1 (718) 213 4904 Website: www.reportbuyer.com
Advertisement
Idiopathic pulmonary fibrosis (IPF) is a progressive disease that results in the scarring of lung tissue and changes the lung's ability to function normally.The most common signs and symptoms of idiopathic pulmonary fibrosis are dyspnea and a persistent nonproductive cough.
Advertisement
Many affected individuals also experience a loss of appetite and gradual weight loss.IPF primarily occurs in older adults.
However, the causes are unknown.
The report "Idiopathic Pulmonary Fibrosis: Competitive Landscape to 2026", uses in-house analyst expertise to provide a competitive assessment of the disease marketplace.
This report provides -- The IPF pipeline consists of 132 drugs spanning all stages of development with approximately two-third of the drugs in the preclinical stage. The strength of the IPF pipeline is strong with 14 drugs, all with novel MOAs, in late-stage clinical development- Close to 43% of IPF clinical trials have been conducted in North America between 2010-2017. 66 clinical trials were recorded in North America between 2010-2017Overall, IPF clinical trials have had relatively high enrollment efficiencies in all phases except for Phase III, which had close to 84% efficiency- Phase II clinical trials had the highest enrollment efficiency (105%), which could be due to patients being more willing to participate due to increased confidence in the safety and efficacy of a late-stage drug
Companies mentioned: Roche, Boehringer Ingelheim, Zambon, Galapagos NV, Prometic Life Sciences Inc, Novartis, Biogen, Promedior, FibroGen
Scope- Pipeline Assessment-regional breakdown, promising late-stage products, early-stage pipeline by molecule type- Clinical Trials Assessment-trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics- Commercial Assessment-leading marketed products, current and future players- Competitive Landscape Analysis-key market events (2016-2026).
Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global IPF market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Download the full report: https://www.reportbuyer.com/product/5771121/?utm_source=PRN
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +1 (718) 213 4904 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/idiopathic-pulmonary-fibrosis-competitive-landscape-to-2026-300838170.html
SOURCE ReportBuyer
